Sun Pharma to acquire DUSA Pharmaceuticals
Sun Pharmaceutical Industries Limited together with its subsidiaries, Sun Pharma and DUSA Pharmaceuticals, Inc announced that they have entered into a definitive agreement under which Sun Pharma will acquire DUSA, a dermatology company focused on developing and marketing its Levulan (aminolevulinic acid HCl) photodynamic therapy platform.
DUSA’s Levulan combination therapy is approved by FDA for treatment of non-hyperkeratotic actinic keratoses or AKs of the face or scalp. Additionally, DUSA’s BLU-U treatment has been approved by FDA for the treatment of moderate inflammatory acne vulgaris and general dermatological conditions.Levulan is manufactured by DUSA in its FDA approved facility at Wilmington, MA.
Magma Fincorp acquires GE Capital India's Housing Finance business
Magma Fincorp Limited has announced its entry into the housing finance business with the signing of definitive agreements to acquire certain affiliates of GE Capital India.
The transaction closure is subject to standard conditions precedents including relevant regulatory approvals. The transaction includes acquisition of:
100% equity share capital of GE Money Housing Finance (“GEMHF”) with Rs. 660 crores housing finance loan assets and Rs. 193 crores net worth as of 31 March 2012; and
100% of the home equity loans portfolio of GE Money Financial Services Private Limited (“GEMFSPL”) with Rs. 940 crores loan assets at 31 May 2012